Atopix Therapeutics Limited

Oxagen Limited

Frank Schroer

Mark Whittaker

Graham Michael Wynne

Richard Edward Armer

Eric Roy Pettipher

Julia Vile

Compounds of general formula (II) wherein

Compounds having CRTH2 antagonist activity

Compounds of general formula (I) whereinW is chloro or fluoro;Ris phenyl optionally substituted with one or more substituents, selected from halo, &#x2014;CN, &#x2014;C-Calkyl, &#x2014;SOR, &#x2014;SOR, &#x2014;SON(R), &#x2014;N(R), &#x2014;NRC(O)R, &#x2014;COR, &#x2014;CONRR, &#x2014;NO, &#x2014;OR, &#x2014;SR, &#x2014;O(CH)OR, or &#x2014;O(CH)O(CH)ORwherein

Compounds of general formula (II) whereinW is chloro or fluoro;Ris phenyl optionally substituted with one or more substituents, selected from halo, &#x2014;CN, &#x2014;C-Calkyl, &#x2014;SOR, &#x2014;SOR, &#x2014;SON(R), &#x2014;N(R), &#x2014;NRC(O)R, &#x2014;COR, &#x2014;CONRR, &#x2014;NO, &#x2014;OR, &#x2014;SR, &#x2014;O(CH)OR, or &#x2014;O(CH)O(CH)ORwherein

Growing community of inventors

Oxon, United Kingdom

Frank Schroer